Unraveling the Mechanism: How Aspirin Impacts the Immune System
The Cambridge researchers have delved into understanding how the immune system interacts with metastasizing cancer cells. They hypothesized that lone cancer cells, having detached from the primary tumour, are more vulnerable to attack by the body’s T-Cells than cancer cells within the larger, initially established tumour mass. This is because the tumour microenvironment often suppresses the immune system, allowing cancer cells to evade detection and destruction.
To investigate this hypothesis, the researchers conducted a series of experiments in mice, screening hundreds of genes to identify those that play a role in cancer metastasis. One gene, which makes a protein called ARHGEF1, stood out. Mice lacking this gene exhibited significantly less metastasis of various primary cancers to the lungs and liver.
This finding led the researchers to investigate the function of ARHGEF1. They discovered that this protein suppresses T-cells, a critical type of immune cell responsible for recognizing and killing cancer cells. T cells patrol the body, scanning for abnormal cells. When they encounter a cell displaying cancer-specific antigens on its surface, they become activated and launch an attack, destroying the cancerous cell.
However, ARHGEF1 interferes with this process by inhibiting T-cell activation. By suppressing T cells, ARHGEF1 effectively shields cancer cells from attack by T-cells, allowing them to spread and establish metastases.
Read More: Rectal Cancer Vanishes After Immunotherapy Trial, Now Classified as FDA Breakthrough Therapy